Clinical and laboratory characterization of a large cohort of patients with Castleman disease retrospectively collected from a single center

References

• Castleman B, Iverson L, Menendez V P. Localized mediastinal lymph node hyperplasia resembling thymoma. Cancer 1956; 9: 822–830
   PubMed Web of Science ®Google Scholar
• Herrada J, Cabanillas F, Rice L, et al. The clinical behavior of localized and multicentric Castleman disease. Ann Intern 1998; 128: 657–662
   PubMed Web of Science ®Google Scholar
• Bowne W B, Lewis J J, Filippa D A, et al. The management of unicentricand multicentric Castleman's disease: a report of 16 cases and a review of the literature. Cancer 1999; 85: 706–717
   PubMed Web of Science ®Google Scholar
• Nikolskaia O V, Nousari C H, Anhalt G J. Paraneoplastic pemphigus in association with Castleman's disease. Br J Dermatol 2003; 149: 1143–1151
   PubMed Web of Science ®Google Scholar
• Casper C. The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care. Br J Dermatol 2005; 129: 3–17
   Web of Science ®Google Scholar
• Mylona E E, Baraboutis I G, Lekakis L J, et al. Multicentric Castleman's disease in HIV infection: a systematic review of the literature. AIDS Rev 2008; 10: 25–35
   PubMed Web of Science ®Google Scholar
• Wang L, Bu D F, Yang Y, et al. Castleman's tumours and production of autoantibody in paraneoplastic pemphigus. Lancet 2004; 363: 525–531
   PubMed Web of Science ®Google Scholar
• Zhu X J, Wang J, Chen X X, et al. Castleman's disease complicating with paraneoplastic pemphigus – a report of 10 cases. Chinese J Dermatol 2005; 38: 745–747
   Google Scholar
• Lv J C, Zhang H, Zhou F D, et al. Anti-glomerular basement membrane disease associated with Castleman's disease. Am J Med Sci 2009; 337
   PubMed Web of Science ®Google Scholar
• Greer J P, Macon W R, McCurley T L, . Non-Hodgkin's lymphoma. Witrobe's Clinical Hematology, G R Lee, J Foerster, J Luken, , et al. Williams & Wilkins, Baltimore, PA 1999; 2463
   Google Scholar
• Wang J, Zhu X, Li R, et al. Paraneoplastic pemphigus associated with Castleman tumor: a commonly reported subtype of paraneoplastic pemphigus in China. Arch Dermatol 2005; 141: 1285–1293
   PubMed Web of Science ®Google Scholar
• Anhalt G J, Kim S C, Stanley J R, et al. Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 1990; 323: 1729–1735
   PubMed Web of Science ®Google Scholar
• Jansen T, Plewig G, Anhalt G J. Paraneoplastic pemphigus with clinical features of erosive lichen planus associated with Castleman's tumor. Dermatology 1995; 190: 245–250
   PubMed Web of Science ®Google Scholar
• Ruggieri G, Barsotti P, Coppola G, et al. Membranous nephropathy associated with giant lymph node hyperplasia. A case report with histological and ultrastructural studies. Am J Nephrol 1990; 10: 323–328
   PubMed Web of Science ®Google Scholar
• Frøkjaer T O, Ladefoged J. Castleman's disease with renal infiltration by polyclonal plasma cells. Clin Nephrol 1998; 49: 328–330
   PubMed Web of Science ®Google Scholar
• Lui S L, Chan K W, Li F K, et al. Castleman's disease and mesangial proliferative glomerulonephritis: the role of interleukin-6. Nephron 1998; 78: 323–327
   PubMed Web of Science ®Google Scholar
• Miadonna A, Salmaso C, Palazzi P, et al. Fibrillary glomerulonephritis in Castleman's disease. Leuk Lymphoma 1998; 28: 429–435
   PubMed Web of Science ®Google Scholar
• Sugimoto T, Ito J, Takeda N, et al. A case of castleman's disease complicated with nephrotic syndrome due to glomerulopathy mimicking membranoproliferative glomerulonephritis. Am J Med Sci 2008; 335: 495–498
   PubMed Web of Science ®Google Scholar
• Rojas R, Martin C, Roman J, et al. Autoimmune haemolytic anaemia presenting 9 years prior to Castleman's disease. Br J Haematol 1994; 86: 431–432
   PubMed Web of Science ®Google Scholar
• Liberato N L, Bollati P, Chiofalo F, et al. Autoimmune hemolytic anemia in multicentric Castleman's disease. Haematologica 1996; 81: 40–43
   PubMed Web of Science ®Google Scholar
• Lerza R, Castello G, Truini M, et al. Splenectomy induced complete remission in a patient with multicentric Castleman's disease and autoimmune hemolytic anemia. Ann Hematol 1999; 78: 193–196
   PubMed Web of Science ®Google Scholar
• Quinn J P, Gilligan O M, Horgan M. Evan's syndrome complicating multicentric Castleman's disease – dramatic response to rituximab. Eur J Haematol 2004; 73: 384–385
   PubMed Web of Science ®Google Scholar
• D'Arena G, Cascavilla N. Chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. Leuk Lymphoma 2007; 48: 1072–1080
   PubMed Web of Science ®Google Scholar
• Galletti J, Cañones C, Morande P, et al. Chronic lymphocytic leukemia cells bind and present the erythrocyte protein band 3: possible role as initiators of autoimmune hemolytic anemia. J Immunol 2008; 181: 3674–3683
   PubMed Web of Science ®Google Scholar
• Soulier J, Grollet L, Oksenhendler E. Molecular analysis of clonality in Castleman's disease. Blood 1995; 86: 1131–1138
   PubMed Web of Science ®Google Scholar
• Hanson C A, Frizzera G, Patton D F, et al. Clonal rearrangement for immunoglobulin and T-cell receptor genes in systemic Castleman's disease. Association with Epstein-Barr virus. Am J Pathol 1988; 131: 84–91
   PubMed Web of Science ®Google Scholar
• Hall P A, Donaghy M, Cotter F E, et al. An immunohistological and genotypic study of the plasma cell form of Castleman's disease. Histopathology 1989; 14: 333–346
   PubMed Web of Science ®Google Scholar
• Ohyashiki J H, Ohyashiki K, Kawakubo K, et al. Molecular genetic, cytogenetic, and immunophenotypic analyses in Castleman's disease of the plasma cell type. Am J Clin Pathol 1994; 101: 290–295
   PubMed Web of Science ®Google Scholar
• Beck J T, Hsu S M, Wijdenes J, et al. Alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med 1994; 330: 602–605
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Sasai M, Shima Y, et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 2000; 95: 56–61
   PubMed Web of Science ®Google Scholar
• Matsuyama M, Suzuki T, Tsuboi H, et al. Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease. Intern Med 2007; 46: 771–774
   PubMed Web of Science ®Google Scholar
• Lee F C, Merchant S H. Alleviation of systemic manifestations of multicentric Castleman's disease by thalidomide. Am J Hematol 2003; 73: 48–53
   PubMed Web of Science ®Google Scholar
• Menegato M A, Canelles M F, Tonutti E, et al. Remission of nephrotic syndrome after thalidomide therapy in a patient with Castleman's disease. Clin Nephrol 2004; 61: 352–356
   PubMed Web of Science ®Google Scholar
• Starkey C R, Joste N E, Lee F C. Near-total resolution of multicentric Castleman disease by prolonged treatment with thalidomide. Am J Hematol 2006; 81: 303–304
   PubMed Web of Science ®Google Scholar
• Corbellino M, Bestetti G, Scalamogna C, et al. Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood 2001; 98: 3473–3475
   PubMed Web of Science ®Google Scholar
• Gérard L, Bérezné A, Galicier L, et al. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial. J Clin Oncol 2007; 25: 3350–3356
   PubMed Web of Science ®Google Scholar
• Hess G, Wagner V, Kreft A, et al. Effects of bortezomib on pro-inflammatory cytokine levels and transfusion dependency in a patient with multicentric Castleman disease. Br J Haematol 2006; 134: 544–545
   PubMed Web of Science ®Google Scholar
• Chang Y, Cesarman E, Pessin M S, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266: 1865–1869
   PubMed Web of Science ®Google Scholar
• Guihot A, Oksenhendler E, Galicier L, et al. Multicentric Castleman disease is associated with polyfunctional effector memory HHV-8-specific CD8+ T cells. Blood 2008; 111: 1387–1395
   PubMed Web of Science ®Google Scholar